Trenson L, Trenson S, van Nes F, et al. - In this real-world analysis of patients treated with liraglutide, compliance with liraglutide treatment over the initial 4-month period as well as a significant weight loss, regardless of the maximally tolerated maintenance dose, was evident in most of these patients. A small but significant additional weight loss was achieved with the addition of metformin.

• In this single-center retrospective cohort study, liraglutide on top of lifestyle adaptations was prescribed to 115 patients (77% female), with a median age of 47 years, a median body weight of 98.4 kg, a BMI of 34.8 kg/m ² , and an HbA1c level of 5.6%; of these, five (4%) patients did not actually start treatment, 9 (8%) discontinued, and 8 (7%) were lost to follow-up.

• A significant reduction in the median body weight by 9.2% to 90.8 (IQR 82.0–103.5) kg, was observed at the 4-month visit.

• Loss of 8.0 (IQR 5.8–10.4) kg was achieved with use of 3.0 mg/day (n = 60).

• Patients using a lower daily dose due to intolerance also showed similar weight loss: 7.4 (IQR 6.2–9.6) kg for 1.2 mg (n = 3), 7.8 (IQR 4.1–7.8) kg for 1.8 mg (n = 16), and 9.0 (IQR 4.8–10.7) kg for 2.4 mg/day (n = 14).

• Initiating metformin <3 months before the start of liraglutide was associated with an additional weight reduction of 1.8 kg.

• Gastrointestinal complaints (n = 5/9) and drug cost (n = 2/9) were the main causes for liraglutide discontinuation.